Kornimate/medical-research-clean huggingface dataset:
effectiveness of dry needling and stretching in people with fibromyalgia.

Conditions: Dry Needling; Stretch; Fibromyalgia

Summary: effectiveness of dry needling and stretching on joint range and myofascial pain at the cervical level in people with fibromyalgia

a randomised clinical trial will be conducted in which there will be 3 groups. one control group and 2 experimental groups; one of them will undergo dry needling of the upper trapezius fibres and the other will undergo passive stretching of the upper trapezius fibres. both groups will have the joint range of cervical lateral tilt, pain measurement by algometer and visual analogue scale (vas) measured. all these measurements will be taken before and after treatment. the participants of the study will be people who have been diagnosed with fibromyalgia at least 6 months before the start of the study, who are members of the fibrofamur association. association of fibromyalgia, chronic fatigue, rheumatic and musculoskeletal diseases of murcia. the data collected will be: socio-demographic data, age, sex, measurement of cervical joint range using a goniometer and measurement of pain using an algometer and visual analogue scale (vas). as undesirable effects, in exceptional cases, the dry needling technique may produce residual discomfort in the puncture area that may last between 1 and 3 days.

Eligibility criteria:
inclusion criteria: * have a diagnosis of fibromyalgia at least six months before the start of the study. * be of legal age. * report at least one episode of neck pain in the last six months. exclusion criteria: * surgical interventions or scars at cervical level. * dizziness or vertigo. * dermatological problems. * severe psychiatric disorders.

Keywords: dry needling stretch fibromyalgia physical therapy
protocol tarc-abpa

Conditions: Allergic Broncho-Pulmonary Aspergillosis

Summary: the main objective of this study is to determine if a doubling of serum tarc (compared to baseline) is associated with the occurrence of exacerbations of abpa. the secondary objectives of the study are : 1. to investigate if induced sputum eosinophils count (compared to baseline) is associated with the occurrence of exacerbations. 2. to examine if the exhaled no (compared to a baseline) is associated with the occurrence of exacerbations. 3. to investigate if activation of circulating t cells (compared to a baseline) is associated with the occurrence of exacerbations. 4. to examine if the rate of specific asp f igg measured by elisa (compared to a baseline) is associated with the occurrence of exacerbations. 5. to determine if the variation of one of the markers above, tarc or asp f specific ige measured at baseline, may be associated with the radiological stage of the disease (abpa-s, abpa-cb, abpa-orf). 6. to investigate if there is a link between fungal exposure at home (visually assessed by the contamination level and the proportion of positive samples for asp. f) and the frequency of exacerbations. 7. to establish if some of the clinical, functional or biological data studied are associated with the frequency of exacerbations.


Eligibility criteria:
pre-inclusion criteria : * major patients, of indifferent sex, * patients insured, * patients accepting to give, after information, their signed informed consent form, * patients affected by abpa, * patients in remission without treatment, or stable under current treatment for at least 3 months. inclusion criteria : this inclusion will be definitive in v1, if : * the pre-inclusion criteria are respected, * the patient has not presented any exacerbation since v0 thereby define a basic state. if patient could not be included, it will be possible to re-screen him for the study, provided he meets the pre-inclusion and inclusion criteria. in this case, a new v0 will be scheduled at least 3 months after the first v0. exclusion criteria : * minor patients, * adults under guardianship, * pregnant or lactating women, * patients unable to follow the protocol or to give consent, * patients with an infection of the lower respiratory tract in the 4 weeks preceding v0 or between v0 and v1, * patients who were hospitalized for respiratory problems in the 4 weeks preceding v0 or between v0 and v1, * patients with chronic inflammatory diseases unrelated to abpa which could influence the results, * patients with cancer, * patients followed for cystic fibrosis defined by a positive sweat test, * patients with known compliance problems identified prior to the study.

Keywords: allergic broncho-pulmonary aspergillosis
evaluation of non-compressive myelopathy in a sample of egyptian patients

Conditions: Myelopathy; Non-Compressive

Summary: an observational study will be conducted in the department of neurology at alazhar university hospitals to study the etiological factors of non-compressive myelopathy in a sample of egyptian patients

myelopathy is a collective term referring to any pathologic condition or neurologic deficit related to the spinal cord. myelopathies are a frequent and potentially disabling neurologic emergency.(sarbu et al., 2019). diseases of the spinal cord often have devastating consequences and imaging studies are indispensable for their diagnosis. the diagnostic approach must be based on the clinical context, the time elapsed since the onset of symptoms and signs, and the imaging findings (herrera et al., 2020). myelopathies may be compressive or non-compressive, regarding to subarachnoid space obstruction (kundu et al., 2018). noncompressive myelopathy (ncm) is described as "spinal cord involvement without detectable clinical and radiological evidence of spinal cord compression causing neurological deficit (thangaraj et al., 2019). there have been a few studies that have investigated noncompressive myelopathy (ncm) in africa as part of nontraumatic myelopathy. with very few studies focusing on nmosd, most of them focus on extrinsic compression and infectious diseases as important causes of myelopathy (musubire et al., 2021) comprehensive data on egyptian patients with non-compressive myelopathy (ncm) in the light of newer diagnostic criteria and serological tests are lacking. no study has been conducted to study the clinico-radiological profile of non-compressive myelopathy (ncm) so far. in this study, we are putting an effort to convey our experience on etiological pattern of non-compressive myelopathy (ncm) with special reference to its radiological features.

Eligibility criteria:
inclusion criteria: - patients with acute, subacute, or chronic neurologic dysfunction (motor and sensory deficit, sphincteric involvement, and a well-defined upper sensory segmental level) consistent with myelopathy (with or without coexisting encephalopathy, neuropathy, or radiculopathy). exclusion criteria: * 1) patients of myelopathy who did not undergo magnetic resonance imaging (mri) of the spinal cord. 2) spinal cord compression on mri explaining patient's neurologic dysfunction. 3) history of previous trauma, acute coma and patients with definite cerebral symptoms incompatible with spinal pathology (e.g., aphasia, hemianopia, neglect, facial involvement). 4) motor neuron disease (mnd) 5)degenerative ataxias.
cardiovascular magnetic resonance guided insertion of implantable cardiac defibrillator in dilated cardiomyopathy

Conditions: Dilated Cardiomyopathy; Left Ventricular Systolic Dysfunction; Fibrosis Myocardial

Summary: cmr guide dcm is a randomized controlled trial with a registry for non-randomized patients. patients enrolled will have non-ischemic cardiomyopathy (nicm) with mild to severe left ventricular (lv) systolic dysfunction with replacement fibrosis identified on cardiac magnetic resonance (cmr). 954 patients will be randomised from 50 sites across 4-6 countries worldwide to receive an implantable defibrillator (icd) or implantable loop recorder (ilr). device and clinical follow-up will be performed at 3, 6, 12, 24, 36 months and at end of study.

the planned research will have two components: a prospective, blocked, randomized, controlled trial of primary prophylaxis icd therapy or ilr insertion in patients with lvef \<45% and late gadolinium enhancement (lge) on cmr and a prospective observational registry of patients with lvef \<45% and no lge on cmr. registry patients will not have an intervention but will have the same follow up frequency as the randomized patients. the primary objective is to determine if routine cmr guided management strategy of implantable defibrillator (icd) insertion reduces total mortality compared to a conservative strategy of implantable loop recorder (ilr) insertion and standard care. the secondary objectives include: * to determine if routine cmr guided management strategy of icd insertion reduces sudden cardiac death (scd) compared to a conservative strategy of ilr insertion and standard care. * to ascertain the rate of scd in patients with dcm and lge scar across a wide range of left ventricular ejection fraction (lvef). statistical analysis will be performed on an intention-to-treat basis. the main analysis of time to death from any cause will be performed using a log- rank test.

Eligibility criteria:
inclusion criteria: * age greater than/equal to 18 years old * non-ischemic cardiomyopathy of dilated type * left ventricular ejection fraction \< 45% * able and willing to comply with all pre, post and follow-up testing and requirements * on maximum tolerated doses of angiotensin converting enzyme (ace) inhibitors (or angiotensin receptor blockers(arb) or neprilysin inhibitors) and beta blockers exclusion criteria: 1. known coronary artery disease (cad) (history of myocardial infarction or significant epicardial cad on angiography) 2. hypertrophic cardiomyopathy 3. cardiomyopathy related to sarcoidosis 4. arrhythmogenic right ventricular dysplasia 5. standard lge cmr contraindications (e.g. severe claustrophobia, metal) 6. currently implanted permanent pacemaker and/or pacemaker/icd lead 7. clinical indication for icd or pacemaker or cardiac resynchronisation therapy 8. contraindications to intravenous gadolinium 9. severe renal insufficiency (egfr\< 45mls/min/1.73m2 ) 10. new york heart association heart failure functional class iv 11. conditions associated with life expectancy \<1 year 12. pregnancy or in females of child-bearing potential, the non-use of accepted forms of contraception
the impact of botox® during robotic rehabilitation of the wrist following stroke

Conditions: Stroke

Summary: the purpose of this study is to see whether treating subjects for wrist rehabilitation following stroke with botox® and robotic therapy is more effective than treatment with robotic therapy alone and no botox®.

this study will explore new ways to facilitate rehabilitation of wrist function after stroke. one of the challenges of recovery is muscle stiffness or excessive muscle tone that often limits exercise or therapy progress. taking this into account, the investigators propose treating the wrist and forearm with a combination of a one-time botox® injection and a 6-week robotic therapy protocol to maximize recovery. botox® is a drug that is injected directly into a muscle to temporarily relax the muscle. botox® is commonly used to decrease muscle tone in tight muscles in the stroke population. robotics therapy provides highly repetitive mass practice with visual and haptic feedback. subjects will be randomized to two groups. group a will receive the botox® injection and group b will receive a placebo saline injection. both groups will receive the same robotics therapy protocol. subjects and investigators will be blinded to group assignment. the investigators would like to know if there are trends between groups in a variety of outcome measures depending on what intervention they received. the investigators predict that the treatment group will have better results than the control group on the fugl meyer, our primary outcome measure. the investigators hope the results of this pilot study will guide development of a larger clinical trial.

Eligibility criteria:
inclusion criteria: * \> 6 months post-stroke * single stroke * ashworth scale of \> 2 but \< 4 for wrist flexors and pronators * able to follow multiple step directions * completed all active occupational therapy * motor strength \> 1/5 at the wrist extension and supination * passive rom of 0-45 degrees at wrist flexion and extension, 0-20 degrees at radial deviation, 0-20 degrees at ulnar deviation, 0-45 degrees at pronation and supination * no botox® injection in the wrist/forearm muscles for at least 12 months * naïve to robotics study protocol exclusion criteria: * joint contracture and wrist or forearm

Keywords: hemiparesis robotics stroke botox® rehabilitation wrist spasticity
a study of mirikizumab (ly3074828) in participants with crohn's disease

Conditions: Crohn's Disease

Summary: the reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active crohn's disease.


Eligibility criteria:
inclusion criteria: * diagnosis of cd for at least 3 months prior to baseline * confirmed diagnosis of moderate to severe cd as assessed by sf, ap score, and ses-cd * demonstrated intolerance, loss of response or inadequate response to conventional or to biologic therapy for cd * if female, subject must meet the contraception recommendations exclusion criteria: * have a current diagnosis of ulcerative colitis, inflammatory bowel disease-unclassified (ibd-u) (formerly known as indeterminate colitis) or short bowel syndrome * currently have or are suspected to have an abscess. recent cutaneous and perianal abscesses are not exclusionary if drained, adequately treated and resolved at least 3 weeks prior to baseline or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery * have a stoma, ileoanal pouch or ostomy * have had a bowel resection within 6 months, or any kind of intra-abdominal or extra abdominal surgery within 3 months of baseline * have ever received any monoclonal antibodies binding il-23
lupus-best - treat-to-target in systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: multicenter, national, two-armed cluster-randomized controlled trial to evaluate the effect of a treat-to-target (t2t) strategy in in systemic lupus erythematosus (sle). 14 centers will be randomized 1:1 to t2t or standard of care. per arm 303 patients with sle who are not in remission will be included and receive either tight control with 6-weekly visits with the aim to reach remission or soc with control visits and treatment adjustment according to the physicians discretion. study duration is 120 weeks using damage accrual and health related quality of life as major outcomes.

this is a multicenter, national, two-armed cluster-randomized controlled trial to evaluate the effect of a treat-to-target (t2t) strategy in in systemic lupus erythematosus (sle) on damage progression and health related quality of life (hrqol). the study centers will be assigned 1:1 to standard of care (soc) or remission, defined as the absence of clinical disease activity (clinical sledai =0) and prednisolone ≤5mg/day and physician global assessment (pga) \ 18 years of age who are not in remission will be eligible. per arm, 303 patients will be included. intervention centers receive a standardized training on t2t and shared decision making (sdm). in the intervention centers, patients not on target enter a phase of tight control with 6-weekly visits and treatment adjustments (at least 4 visits) or until remission is reached and maintained. patients in remission are reassessed every 12 weeks. in case of flare, they can re-enter tight control based on sdm. in the soc arm, patients receive 3- to 6-monthly controls and treatment adjustments according to the physician's discretion. study duration is 120 weeks using damage accrual and hrqol as major outcomes.

Eligibility criteria:
inclusion criteria: * patients with sle according to validated classification criteria * age at least 18 years * not in a stage of remission due to 1. clinical sledai \> 0 and/or 2. gc dosage above 5 mg prednisone equivalent per day and/or 3. physician global assessment ≥ 0.5 on a visual analogue scale (vas) from 0 to 3 * fluent german language skills * written informed consent exclusion criteria: * participation in other interventional trial(s) * any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or is considered unsuitable by the investigator for any other reason. examples could be: * life-threatening sle manifestations that require intensive care treatment * active life-threatening diseases other than sle * active malignancies * acute and chronic infections that do not allow the intensification of immunosuppressive treatment

Keywords: treat-to-target shared decision making
does vildagliptin affect portal vein pressure in patients with type 2 diabetes mellitus? a cross sectional study

Conditions: Drug Mechanism; Drug Usage

Summary: this study investigated how vildagliptin (a di-peptidyl peptidase 4 inhibitor) affects portal vein pressure and hepatosteatosis in patients with type 2 diabetes mellitus.

group 1 used metformin (1000 mg bid) and gliclazide (60 mg qd); group 2 used the same amounts of metformin and gliclazide, with the addition of vildagliptin (50 mg bid). the patients were prospectively assigned to each of these two groups for the purpose of this study. using doppler ultrasound, all cases were measured for portal vein flow velocity, portal vein flow and portal vein diameter. degree of hepatosteatosis was also recorded.

Eligibility criteria:
inclusion criteria: -type 2 dm cases and at least 3 months used the same drugs (metformin and gliclazide or metformin and gliclazide and vildagliptin) exclusion criteria: * used alcohol and cigarettes * chronic liver disease, * chronic renal failure, * active infection * patients using certain drugs which may affect portal pressure such as propronalol, * calcium channel blockers, * angiotensin-converting enzyme inhibitors, * angiotensin receptor blockers and isosorbit monohydrate

Keywords: vildagliptin portal vein pressure hepatosteatosis
efficacy and safety of weak extremely low frequency electromagnetic fields in mild and moderate essential hypertension

Conditions: Essential Hypertension

Summary: this study will evaluate the efficacy and safety of weak extremely low frequency electromagnetic fields (elf-emf) in mild and moderate essential hypertension.


Eligibility criteria:
inclusion criteria: * ages: 20 years to 74 years * genders : both * the severity of hypertension: mild and moderate (who/ish criteria stage i-ii) systolic blood pressure (sbp) \>/= 140 and/or diastolic blood pressure (dbp)\>/= 90 (untreated hypertension cases) exclusion criteria: * any of the following medical conditions: * severe essential hypertension (dbp \>110) * secondary or malignant hypertension * history or symptoms of cerebral vascular disease * history of myocardial infarction * history of angina pectoris, atrial fibrillation, heart failure and arrhythmia * renal dysfunction (serum creatinine \> 2.1mg/dl) * severe hepatic dysfunction * uncontrolled diabetes * allergy, drug sensitivity or chronic skin disease * peptic ulcer disease * current pregnancy or lactation * depression that needs to be treated * hypertension controlled with antihypertensive medication
immediate functional versus non functional implant loading in the mandible

Conditions: Dental Implants; Edentulous Alveolar Ridge

Summary: comparing immediate functionally loaded implants and immediate non functionally loaded implants in the posterior mandibular region on bases of bone density and bone loss evaluated by cone-beam computed tomography (cbct).

patients are more demanding after the revolution in immediate implant dentistry which reduces implant procedure nowadays according to literature and research. in response to patients' demands not only implants are immediately placed but also immediately loaded within 72 hours reducing the time for prosthetic loading and also improving bone formation according to some studies. the debate in modern implant dentistry is whether to immediately load the implants in functional occlusion or non-functional occlusion and which will improve the osseointegration and reduce crestal bone loss. implants of the bioinfinity system were placed in 16 subjects divided into two groups. group (a): 8 patients with missing posterior mandibular teeth whom will be rehabilitated with immediate functionally loaded implants. group (b): 8 patients with missing posterior mandibular teeth in whom immediate non-functionally loaded implants were used. the two groups were evaluated at baseline, immediately after implant placement and 4 months postoperative to evaluate crestal bone level and quantitative radiographic bone density using cbct.

Eligibility criteria:
inclusion criteria: * adult patients aged (20-40) years old. * missing posterior tooth or teeth indicated for implant placement. * residual alveolar ridge at least 10 mm high and at least 4 mm wide. exclusion criteria: * systemic diseases that will contraindicate the surgery. * poor oral hygiene. * the patient refuses to undergo the surgery. * parafunctional habits.
prognosis factors in patients with primary central nervous system lymphoma

Conditions: PCNSL; Survival Analysis

Summary: primary central nervous system lymphoma (pcnsl) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. it accounts for about 4% of all intracranial tumors and 4% to 6% of all non-hodgkin's lymphomas . among them, the most common type is diffuse large b cell lymphoma (dlbcl), accounting for about 95% of all cases. high dose methotrexate (hd-mtx) based chemotherapy can improve the prognosis of patients, but only 30% to 40% of patients can achieve sustained remission, and the overall prognosis is very poor\[4, 6\]. currently, the international extranodal lymphoma study group (ieslg) prognostic scoring system and the memorial sloan kettering cancer center (mskcc) prognostic index are widely used to evaluate the prognosis in patients with pcnsl. however, ieslg model has some limitations such as the relatively small number of patients and short follow-up period. mskcc model may have an inherent selection bias because retrospective data were collected from a single large institution. therefore, there is a urgent need to identify novel indicators for prognosis evaluation and risk stratification in pcnsl patients.


Eligibility criteria:
inclusion criteria: (i)the pathological biopsy and immunohistochemistry diagnosis were pcnsl according to who diagnostic criteria for pcnsl in 2016. (ii) no treatment has been received. (iii)there were no diseases with malignant tumor, serious infection, other blood system diseases, immune system diseases and other conditions which may have great influence on peripheral blood lymphocyte count. (iv) the clinical data were complete. exclusion criteria: -